Thank you for sharing, Cristina!
21.10.2025 11:21
👍 1
🔁 0
💬 0
📌 0
Thank you for sharing, Cristina!
📅 Coming next week, October 23, 2025, at 5:00 PM (CEST) #Nephsky #Medsky
✨E-seminar: Interventional Nephrology- A Beginner’s Guide for Young Nephrologists
🎙️Presenting @drbarbateba.bsky.social
💬Moderator @hugodiniz.medsky.social
👉You can register here
www.era-online.org/video-pages/...
Look mom! I am on Bluesky ☺️ #ERA25
Thank you so much for attending and sharing our session 🤩
Next time, come say hi 👋
Yeah. Hopefully the group with HFrEF gets some benefit 🤞
Electronic Communication Committee getting their diplomas of merit at the Presidential dinner from the President Prof. @rosertorra.bsky.social #ERA25 ☺️
Yes @lonniepyne.bsky.social was the presenter! Hopefully he might sneak in to give his thoughts on the matter #ERA25
Also, the last author presented a new meta analysis with ACHIEVE and ALCHEMIST. Considering only studies with low risk of bias, still no evidence of positive effect @hswapnil.medsky.social
So, about that. @pepasolerr.bsky.social asked about stratification by LVEF/echo data. Looks like only a small % had echo at baseline, but during follow up most patients got one. The author said they are going to look into that #ERA25
Sorry, the app might have bugged on me. Are you talking about the Spironolactone trial? This replies are under the sglt2i aki analysis
Me neither, but the study was well designed to answer the question. Regarding HF, I don't think so, but they basically used all the Empagliflozin trials for the analysis
Prof Anders made a case for the (im)balance between workload (hyperfiltration) and nephron mass as the key interaction
DM is a risk factor - there are no diabetic HF or diabetic cerebral vascular disease. Most cases are probably multifactorial
HTN ckd probably doesnt exist and most are genetic
Vlado Perkovic discussing Sibeprenlimab (APRIL binder) at Late Breaking Clinic Trials II at #era25. Great to see Oceanians (Aus/NZers) on stage!
Wasn't aware of that, thanks! Dr. Walsh mentioned it is already accepted for publication in a major journal #ERA25
ACHIEVE trial - Spironolactone in Hemodialysis stopped early... due to futility 😢
I had some hopes for this one.
#ERA25
iSGLT2 effects on Acute Kidney Outcomes #ERA25
✅ Clear protective effects for AKI
❌ No extra risk of AKI events during the acute eGFR dip
Sibeprenlimab in IgA Nephropathy #ERA25
* Data presented is the 9-month reduction in proteinuria
Visionary interim analysis! #ERA25 massive reduction in proteinuria after 1 year of treatment
Thanks for letting me know 🙏
Reduce the Workload, save your kidneys #ERA25
I agree.
Clinically it doesn’t hurt to try a flozin if a patient with diabetes or HF is on an MRA and has hyperkalemia since flozins are clearly indicated in that patient population
But don’t bank on them to fix the issue - it’s a small effect even if true!
#ERA25 #NephSky
In a bit more detail... #ERA25
Prof. Anders starting with a banger
Diabetic Kidney Disease and Hypertensive Kidney Disease don't exist! 😱 #ERA25
Ah, yes. By the way they presented it looked significant. But, still a small decrease is much better than an increased risk 😁
Yes, the lack of morphological and hemodynamic data about the AVGs was also puzzling #ERA25
#ERA25
@kevinyau.bsky.social GLP1 agonist master Jedi presenting at #ERA25.
💉GLP1 agonist reduce ED visits and hospitalizations!!!
📉Awesome methods. Best of the session:
💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd).
💊Only 40% on SGLT2i!!! We should flozinate more!!!
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.
The first #ERA25 simultaneous pub
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
They are lower, both investigator-reported and K+ > 5.5 right?
Yes! Thank you. Probably too cautious #ERA25 P.S. Love your handle